DM
BBIO icon

Deerfield Management’s BridgeBio Pharma BBIO Stock Holding History

Deerfield Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,000,000
Closed -$16.7M – 121
2021
Q4 		$16.7M Buy
+1,000,000
New +$42.3M 0.35% 63

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Deerfield Management's BBIO Position: Q4 2019 in Review

Deerfield Management sold out of BridgeBio Pharma (BBIO) in Q4 2019, closing a stake of 290,000 shares — an estimated $6.23M sold.

Deerfield Management first reported a position in BBIO in Q2 2019 and held it in 2 quarters. The position peaked at $7.82M in Q2 2019. 88 funds tracked by Wall St. Rank hold BBIO as of Q4 2019.

  • Deerfield Management reported no remaining BridgeBio Pharma position as of Q4 2019 after selling out during the quarter.
  • Deerfield Management sold 290,000 BridgeBio Pharma shares in Q4 2019, an estimated $6.23M.
  • Deerfield Management first reported a position in BridgeBio Pharma in Q2 2019 and held it in 2 quarters.
  • Deerfield Management's BridgeBio Pharma position peaked at $7.82M in Q2 2019.
  • 88 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2019.

Based on Deerfield Management's 13F filing for Q4 2019, filed 14 Feb 2020.